GO:0004239 initiator methionyl aminopeptidase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0004239 (initiator methionyl aminopeptidase activity) catalyzes removal of the N-terminal initiator methionine from nascent peptides, a co-translational modification essential for protein maturation.
• Methionine aminopeptidases (MetAPs) are divided into type 1 (MetAP1) and type 2 (MetAP2) enzymes, with distinct substrate preferences and inhibitor sensitivities.
• MetAP2 is a validated target for angiogenesis inhibition, and its inhibitors have been explored in cancer and age-related macular degeneration.
• Bacterial MetAPs, including those from Escherichia coli and Rickettsia prowazekii, are potential antibiotic targets due to their essential role in protein maturation.
• Species-specific differences, such as a single amino acid change between archaeal and human MetAP2, affect inhibitor binding and can guide selective drug design.
• Yeast MetAP1 provides a tractable model for studying enzyme kinetics and inhibition, with improved purification and assay methods available.
Description
Initiator methionyl aminopeptidase activity (GO:0004239) is a fundamental enzymatic function that removes the N-terminal initiator methionine from newly synthesized proteins. This co-translational modification is critical for protein stability, subcellular localization, and function, as the exposed N-terminus after methionine cleavage often determines whether a protein is targeted for degradation or further processing. The enzymes responsible, methionine aminopeptidases (MetAPs), are conserved across all domains of life and are divided into type 1 (MetAP1) and type 2 (MetAP2) based on sequence and structural features. Researchers study this activity to understand protein maturation pathways, to develop antibiotics targeting bacterial MetAPs, and to design anticancer and anti-angiogenic therapeutics that inhibit human MetAP2. The essential nature of MetAPs in bacteria and their role in angiogenesis in humans make them attractive targets for drug discovery.
initiator methionyl aminopeptidase activity At A Glance
| GO ID | GO:0004239 |
|---|---|
| GO term | initiator methionyl aminopeptidase activity |
| Ontology | molecular_function |
| Synonym | L-methionine aminopeptidase activity, MAP, methionine aminopeptidase activity, peptidase M activity |
| Major function | Catalysis of the release of N-terminal initiator methionine from peptides |
| EC number | 3.4.11.18 |
| Substrates | Peptides with N-terminal initiator methionine and a small second residue |
| Cofactors | Divalent metal ions (e.g., Co2+, Mn2+, Zn2+) depending on the enzyme type |
| Localization | Cytoplasm, ribosome-associated |
What Is GO:0004239?
According to the Gene Ontology, GO:0004239 (initiator methionyl aminopeptidase activity) is defined as the catalysis of the release of N-terminal initiator methionine from peptides. This activity is synonymous with L-methionine aminopeptidase activity, MAP, methionine aminopeptidase activity, and peptidase M activity. It is a molecular function that acts on peptide substrates, specifically cleaving the peptide bond between the initiator methionine and the second amino acid residue, provided the second residue is small (e.g., glycine, alanine, serine, cysteine, threonine, valine). This processing event is often co-translational and is required for the proper function of many proteins.
Why Is initiator methionyl aminopeptidase activity Important in Cell Biology?
Initiator methionyl aminopeptidase activity is essential for protein homeostasis and maturation across all kingdoms of life. In bacteria, MetAPs are required for the removal of the N-terminal methionine from a large fraction of proteins, and their inhibition leads to growth arrest, making them promising antibiotic targets. In humans, MetAP2 is involved in angiogenesis and has been targeted for cancer therapy and for the treatment of age-related macular degeneration. The specificity of MetAPs for the initiator methionine and the second residue determines which proteins are processed, thereby influencing cellular processes such as protein degradation, localization, and activity. Understanding this activity is therefore critical for both basic biology and therapeutic development.
• Essential for protein maturation by removing N-terminal methionine, affecting protein stability and function.
• MetAP2 is a validated target for anti-angiogenic therapy in cancer and macular degeneration.
• Bacterial MetAPs are essential and are explored as targets for novel antibiotics.
• Species-specific differences in MetAP2 can be exploited for selective inhibitor design.
• Yeast MetAP1 serves as a model for enzymatic studies and drug screening.
• Dysregulation of MetAPs has been linked to tumor progression and metastasis.
• MetAP inhibitors can modulate angiogenesis and are in clinical trials for AMD.
• The activity is conserved from archaea to humans, enabling comparative studies.
• It plays a role in the N-end rule pathway by exposing destabilizing residues.
• Inhibitors of MetAP1 from Rickettsia prowazekii show potential for treating rickettsial infections.
What Happens During initiator methionyl aminopeptidase activity?
Substrate Recognition and Binding
In simple terms: The enzyme recognizes the start of a new protein and grabs onto it.
Initiator methionyl aminopeptidase (MetAP) binds to nascent polypeptides as they emerge from the ribosome, recognizing the N-terminal initiator methionine and the adjacent second amino acid residue. The enzyme's active site contains a dinuclear metal center that coordinates the substrate's N-terminus and the carbonyl oxygen of the scissile peptide bond. Substrate specificity is determined by the size of the second residue; small residues such as glycine, alanine, serine, cysteine, threonine, and valine are preferred, while bulky residues prevent cleavage.
Catalytic Cleavage of the Peptide Bond
In simple terms: The enzyme cuts off the methionine like a pair of molecular scissors.
Once bound, the enzyme catalyzes the hydrolysis of the peptide bond between the initiator methionine and the second residue. The metal ions in the active site activate a water molecule, which attacks the carbonyl carbon, leading to the release of the free methionine and the processed peptide. This reaction is highly specific and does not proceed if the second residue is large.
Release of Products and Recycling
In simple terms: After cutting, the enzyme lets go of the protein and is ready to act again.
Following cleavage, the processed peptide is released and can undergo further folding or modifications. The enzyme is then free to bind another substrate. The removal of the initiator methionine can expose a new N-terminal residue that may be subject to further processing, such as acetylation or arginylation, which can affect protein half-life.
Co-translational vs. Post-translational Action
In simple terms: The enzyme can work while the protein is being made or after it is finished.
MetAPs can act co-translationally, binding to the ribosome and processing the nascent chain as it emerges, or post-translationally on already synthesized proteins. The co-translational mode is predominant for many proteins, ensuring timely maturation. The choice between co- and post-translational processing can influence protein folding and stability.
Key Genes Involved in GO:0004239 initiator methionyl aminopeptidase activity
The following genes encode methionine aminopeptidases and related proteins that carry out or regulate initiator methionyl aminopeptidase activity across species.
| Gene | Major Role | Research Relevance |
|---|---|---|
| METAP1 | Human type 1 methionine aminopeptidase; removes initiator methionine from proteins with small second residues | Target for cancer and bacterial inhibition studies; model for enzyme kinetics |
| METAP2 | Human type 2 methionine aminopeptidase; involved in angiogenesis and protein maturation | Validated target for anti-angiogenic drugs (e.g., fumagillin, ovalicin) in cancer and AMD |
| map | Escherichia coli methionine aminopeptidase; essential for bacterial protein maturation | Model for antibiotic development; studied for substrate specificity |
| MAP1 | Saccharomyces cerevisiae methionine aminopeptidase I; removes initiator methionine | Model for enzyme purification and assay development |
| MAP2 | Saccharomyces cerevisiae methionine aminopeptidase II; similar to human MetAP2 | Model for studying MetAP2-specific functions and inhibitor sensitivity |
| RpMAP1 | Rickettsia prowazekii methionine aminopeptidase 1; essential for bacterial survival | Target for antibiotics against rickettsial infections |
| MetAP2 (archaeal) | Archaeal type 2 methionine aminopeptidase; differs from human by one amino acid | Model for understanding inhibitor selectivity and evolution |
| METAP1D | Human mitochondrial methionine aminopeptidase 1D; processes mitochondrial proteins | Potential role in mitochondrial function and disease |
| METAP2 (bovine) | Bovine MetAP2; used in structural studies | Structural insights into inhibitor binding |
| map (Bacillus subtilis) | Bacterial methionine aminopeptidase; essential for growth | Antibiotic target validation |
| map (Mycobacterium tuberculosis) | Methionine aminopeptidase; essential for survival | Target for anti-tuberculosis drugs |
| map (Plasmodium falciparum) | Methionine aminopeptidase; involved in parasite protein maturation | Antimalarial drug target |
| map (Leishmania major) | Methionine aminopeptidase; essential for parasite viability | Target for antiparasitic drugs |
| map (Trypanosoma brucei) | Methionine aminopeptidase; required for growth | Target for sleeping sickness therapy |
| map (Candida albicans) | Methionine aminopeptidase; involved in fungal protein processing | Antifungal target |
| map (Arabidopsis thaliana) | Plant methionine aminopeptidase; role in development | Model for plant protein maturation |
| map (Drosophila melanogaster) | Fruit fly methionine aminopeptidase; essential for development | Genetic model for MetAP function |
| map (Danio rerio) | Zebrafish methionine aminopeptidase; involved in angiogenesis | Model for anti-angiogenic studies |
How Is initiator methionyl aminopeptidase activity Regulated?
Initiator methionyl aminopeptidase activity is regulated at multiple levels. In bacteria, MetAP expression is constitutive but can be modulated by growth conditions. In humans, MetAP2 is regulated by phosphorylation and interacts with eukaryotic initiation factor 2 (eIF2). The activity can be inhibited by specific small molecules such as fumagillin, ovalicin, and their derivatives, which covalently bind to the active site. Additionally, the availability of metal ions (e.g., cobalt, manganese, zinc) influences enzyme activity, as MetAPs require a dinuclear metal center for catalysis. The N-end rule pathway further regulates protein stability based on the exposed N-terminal residue after methionine removal.
initiator methionyl aminopeptidase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| METAP2 | Cancer, angiogenesis, AMD | Knockout or knockdown in endothelial cells; xenograft models |
| METAP1 | Bacterial infections (as target) | Bacterial knockout strains; inhibitor screening |
| METAP2 (archaeal) | Inhibitor selectivity studies | Recombinant protein; structural analysis |
| MAP1 (yeast) | Model for enzyme kinetics | Yeast knockout and overexpression |
| RpMAP1 | Rickettsial infections | In vitro enzyme assays; bacterial growth inhibition |
Cancer and Angiogenesis
MetAP2 is highly expressed in endothelial cells during angiogenesis, and its inhibition blocks endothelial cell proliferation and migration. Inhibitors such as fumagillin and TNP-470 have shown anti-tumor activity in preclinical models by targeting MetAP2. The enzyme is also overexpressed in various cancers, including colorectal and breast cancer, making it a potential therapeutic target.
Age-related Macular Degeneration (AMD)
Choroidal neovascularization (CNV) in AMD is driven by angiogenesis, and MetAP2 inhibitors have been investigated to reduce CNV. Clinical trials have explored MetAP2 inhibitors for AMD, though challenges remain in optimizing efficacy and safety.
Bacterial Infections
Bacterial MetAPs are essential for protein maturation and survival, making them attractive targets for antibiotics. Inhibitors of Rickettsia prowazekii MetAP1 have been identified from the Pandemic Response Box, showing potential for treating rickettsial infections. Similarly, E. coli MetAP is a model for developing broad-spectrum antibiotics.
Parasitic Diseases
MetAPs from protozoan parasites such as Plasmodium falciparum and Leishmania major are essential for parasite viability and are being explored as drug targets. Inhibitors that selectively target parasite MetAPs over human enzymes could provide new antiparasitic therapies.
From initiator methionyl aminopeptidase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| What is the effect of METAP2 knockout on angiogenesis? | Human endothelial cell line (HUVEC) with CRISPR knockout |
| How does a point mutation in the active site affect catalysis? | Recombinant MetAP2 with site-directed mutagenesis |
| Can a tagged MetAP1 be used to study localization? | Knock-in of GFP or FLAG tag at endogenous locus |
| What is the effect of METAP1 overexpression on protein stability? | Stable cell line with inducible overexpression |
| Which proteins are processed by MetAP2? | Knockout cells followed by N-terminomics |
| Can yeast MAP1 complement human METAP1? | Yeast knockout complemented with human gene |
How to Study the initiator methionyl aminopeptidase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Enzymatic assay with Met-Gly-Pro | Methionine release | Kinetic studies and inhibitor screening |
| N-terminomics | N-terminal peptide enrichment | Global substrate identification |
| X-ray crystallography | 3D structure of enzyme-inhibitor complex | Structure-guided drug design |
| CRISPR knockout | Loss of gene function | Phenotypic studies in cells and animals |
| RNAi knockdown | Reduced gene expression | Transient loss-of-function studies |
| Western blot | Protein expression and processing | Validation of MetAP knockout |
| Angiogenesis tube formation assay | Endothelial cell tube formation | Evaluation of MetAP2 inhibitors |
Enzymatic Activity Assays
Initiator methionyl aminopeptidase activity can be measured using synthetic peptide substrates (e.g., Met-Gly-Pro) and detecting released methionine via colorimetric or fluorogenic assays. These assays are used to determine kinetic parameters and to screen inhibitors.
N-Terminomics and Proteomics
Mass spectrometry-based N-terminomics can identify proteins that retain or lose their initiator methionine upon MetAP knockout or inhibition, providing a global view of substrate specificity. This approach reveals the impact of MetAP activity on the proteome.
Structural Biology
X-ray crystallography and cryo-EM have been used to determine the structures of MetAPs from various species, revealing the dinuclear metal center and inhibitor binding modes. These studies guide the design of selective inhibitors.
Genetic Knockout and Knockdown
CRISPR-Cas9 knockout or RNAi knockdown of METAP1 and METAP2 in cell lines and model organisms can reveal their roles in cell proliferation, angiogenesis, and development. Conditional knockouts in mice are used to study tissue-specific functions.
How CRISPR Can Be Used to Study GO:0004239 initiator methionyl aminopeptidase activity
Knockout
CRISPR-Cas9 knockout of METAP1 or METAP2 in human cell lines (e.g., HUVEC, HeLa) can abolish initiator methionyl aminopeptidase activity, leading to accumulation of unprocessed proteins and defects in angiogenesis or proliferation. These models are used to validate the essentiality of MetAPs and to identify downstream targets.
Point Mutation
Introducing point mutations in the catalytic residues of METAP2 (e.g., His231, Asp251) via CRISPR can dissect the contribution of individual residues to catalysis and inhibitor binding. Such models help confirm the mechanism of action of MetAP inhibitors.
Knock-in
Knock-in of a tagged version of METAP1 (e.g., GFP or HA) at the endogenous locus allows real-time imaging and immunoprecipitation to study protein interactions and localization. This approach preserves endogenous regulation.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression of METAP2 can be used to study the effects of increased enzyme levels on angiogenesis and tumor growth. Overexpression models are useful for testing inhibitor efficacy in a background of high enzyme activity.
How EDITGENE Supports initiator methionyl aminopeptidase activity Research
Researchers studying initiator methionyl aminopeptidase activity-related genes often need to determine whether a candidate gene is causally involved in protein maturation, angiogenesis, or bacterial survival. EDITGENE provides a comprehensive suite of CRISPR-based services to create precisely engineered cell models, enabling functional validation and drug discovery.
Contact EDITGENE today to design your custom CRISPR model for initiator methionyl aminopeptidase activity research.
Frequently Asked Questions About initiator methionyl aminopeptidase activity
What is initiator methionyl aminopeptidase activity?
It is the enzymatic activity that removes the N-terminal initiator methionine from newly synthesized proteins, as defined by GO:0004239.
What genes are involved in initiator methionyl aminopeptidase activity?
The main genes are METAP1 and METAP2 in humans, and their homologs in bacteria, yeast, and other organisms.
What is the difference between MetAP1 and MetAP2?
MetAP1 and MetAP2 are two types of methionine aminopeptidases with different sequences, substrate preferences, and inhibitor sensitivities; MetAP2 is the target of anti-angiogenic drugs.
How is initiator methionyl aminopeptidase activity measured?
It is typically measured using synthetic peptide substrates and detecting released methionine, or by N-terminomics to identify processed proteins.
What diseases are associated with MetAP2?
MetAP2 is linked to cancer and age-related macular degeneration due to its role in angiogenesis.
Can MetAP inhibitors be used as antibiotics?
Yes, bacterial MetAPs are essential and inhibitors are being developed as potential antibiotics, including for Rickettsia prowazekii.
What is the role of metal ions in MetAP activity?
MetAPs require a dinuclear metal center (e.g., Co2+, Mn2+, Zn2+) for catalysis, which activates water for peptide bond cleavage.
How does the second amino acid affect methionine cleavage?
Only small residues like glycine, alanine, serine, cysteine, threonine, and valine allow cleavage; bulky residues prevent it.
Is MetAP2 a good drug target for AMD?
Yes, MetAP2 inhibitors have been investigated in clinical trials for AMD to reduce choroidal neovascularization.
What model organisms are used to study MetAPs?
Yeast (Saccharomyces cerevisiae), E. coli, and zebrafish are common models for studying MetAP function and inhibition.
Conclusion
Initiator methionyl aminopeptidase activity (GO:0004239) is a conserved and essential molecular function that removes the N-terminal methionine from nascent proteins, influencing protein stability, localization, and function. Its role in angiogenesis and bacterial survival has made it a prime target for therapeutic development in cancer, AMD, and infectious diseases. Continued research using CRISPR models, enzymatic assays, and proteomics will further illuminate its mechanisms and therapeutic potential.
References
- 1. Wingfield PT. 2017. N-Terminal Methionine Processing.. Curr Protoc Protein Sci 88:6.14.1-6.14.3 PMID: 28369664
- 2. Ehlers T et al.. 2016. Methionine AminoPeptidase Type-2 Inhibitors Targeting Angiogenesis.. Curr Top Med Chem 16(13):1478-88 PMID: 26369821
- 3. Ehrenberg M et al.. 2018. Evolving multidimensional pharmacological approaches to CNV therapy in AMD.. Curr Eye Res 43(2):147-154 PMID: 29111834
- 4. Bradshaw RA et al.. 2002. Methionine aminopeptidases and angiogenesis.. Essays Biochem 38:65-78 PMID: 12463162
- 5. Zheng Y et al.. 2005. Characterization of two new aminopeptidases in Escherichia coli.. J Bacteriol 187(11):3671-7 PMID: 15901689
- 6. Bala S et al.. 2023. A single amino acid difference between archaeal and human type 2 methionine aminopeptidases differentiates their affinity towards ovalicin.. Biochim Biophys Acta Proteins Proteom 1871(2):140881 PMID: 36396098
- 7. Sharma I et al.. 2024. Inhibitors of Rickettsia prowazekii methionine aminopeptidase 1 identified from the Pandemic Response Box.. Bioorg Med Chem Lett 112:129931 PMID: 39154713
- 8. Walker KW et al.. 1999. Yeast (Saccharomyces cerevisiae) methionine aminopeptidase I: rapid purification and improved activity assay.. Biotechnol Appl Biochem 29(2):157-63 PMID: 10075912
